Replimune Group

Replimune Group’s stock rose to a 52-week high of $16.20, well above its yearly low of $1.50. Over the past year the price climbed about 166%, roughly 119% in the last six months and around 61% year-to-date. Analysts consider the stock above its fair value, citing price targets between $14 and $24, and several firms raised their estimates after the accelerated FDA approval of Tudriqev in combination with Nivolumab. » Altro su de.investing.com

Replimune Group’s stock rose to a 52-week high of $15.72 and is currently trading at $15.69, implying a market capitalization of about $1.47 billion. Over the past year the share gained 174.3%, while InvestingPro warns the stock may currently be trading above its fair value. Options data suggest a potential price move of roughly 5.6% ahead of the quarterly results. Several analysts (Wedbush, Leerink, Cantor Fitzgerald) raised their valuations following the FDA approval of Tudriqev and positive prospects for RP-1 in combination with nivolumab. » Altro su de.investing.com

The options market implies an expected 5.6% price move for Replimune Group around the quarterly results expected on August 21; the exact publication date has not yet been confirmed. Historical comparisons show that actual stock reactions to previous quarterly reports sometimes differed markedly from the implied moves, with both larger gains and sizable declines. » Altro su de.investing.com